In addition to the potential use of Gefitinib / PIM kinase inhibitor combination in the treatment of CRPC, this combination may be especially attractive in treatment of EGF driven tumours such as NSCLC in which Gefitinib as a single agent already has significant activity. Here, EGF is linked to neoplasm.